RxDoctor Payments Data

Jeffrey Sugarman

Dermatology · Santa Rosa, CANPI 1548255482

Payments from drug & device makers

$591,826in general payments, 2019–2025

Across 910 payments — averaging $650.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$180K
  • Sanofi$89K
  • Pfizer$66K
  • Incyte Corporation$57K
  • Ultragenyx Pharmaceutical Inc.$48K
  • AbbVie$36K
  • plus $116K from 28 others
$651,485in research payments, 2019–2025

Across 207 payments — averaging $3147.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$608K
  • LEO Pharma AS$31K
  • Pfizer$10K
  • Mayne Pharma Commercial LLC$3K

What the payments were for

  • Consulting fees$130,65126%
  • Speaking & faculty fees$299,54161%
  • Travel & lodging$42,7099%
  • Food & beverage$21,1244%
  • Education$2190%
  • Gifts$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$591,826 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$709,777
Medicare patients
3,346
Services billed
13,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$39,660
Fluocinonide12$452
Clobetasol Propionate15$404
Hydrocortisone15$99
Triamcinolone Acetonide19$74

Paid to pharmacies, not to this prescriber.

Other dermatology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →